bioAffinity Technologies (BIAF) Capital Expenditures (2023 - 2026)

bioAffinity Technologies has disclosed Capital Expenditures across 4 years of filings, most recently posting $5663.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 88.85% year-over-year to $5663.0; the TTM figure through Mar 2026 stood at $15445.0 (down 82.54% YoY), while the FY2025 annual figure was $60568.0, down 23.41% from the prior year.
• Capital Expenditures grew to $5663.0 in Q1 2026, from $1.0 in the prior quarter.
• Over the last five years, Capital Expenditures for BIAF reached as high as $50786.0 in Q1 2025 and fell as low as -$13442.0 in Q4 2023.
• The 4-year median for Capital Expenditures is $5663.0 (2026), against an average of $12939.7.
• Annual changes were most pronounced in 2024 — Capital Expenditures surged 5468.05% — and 2025, when it plunged 138.75%.
• A 4-year view of Capital Expenditures shows it stood at -$13442.0 in 2023, then jumped by 100.01% to $1.0 in 2024, then changed by 0.0% to $1.0 in 2025, then surged by 566200.0% to $5663.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $5663.0, $1.0, and -$3646.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.